Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06335173 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
A Phase 2 study of Alzheimer Disease, sponsored by Acumen Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 542
- Enrollment target
- 20
- Study locations
NCT06335173 is a Phase 2 study of Alzheimer Disease that is active but no longer recruiting, run by Acumen Pharmaceuticals. The registered enrollment target is 542 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06335173, a Phase 2 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Acumen Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 542 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG sabirnetug
Study Locations (20)
Florida
- JEM Research Institute - Atlantis
- Bradenton Research Center - Bradenton
- Gil Fernandez-Yera, MD, PA - Coral Gables
- Brain Matters Research - Delray Beach
- Coral Clinical Research - Homestead
- K2 Medical Research - Villages - Lady Lake
- Finlay Medical Research - Miami
- Aqualane Clinical Research - Naples
- Ocala Health - Family Care Specialists - Ocala I - Ocala
- Progressive Medical Research - Port Orange
- Alzheimer's Research and Treatment Center - Stuart - Stuart
- K2 Medical Research - Tampa - Tampa
California
- The Neurology Center of Southern California - Carlsbad - Carlsbad
- Neurology Center of North Orange County - Fullerton
- Irvine Medical Research - Irvine
- Healthy Brain Research - Long Beach
- Syrentis Clinical Research - Santa Ana
- CenExel - California Neuroscience Research Medical Group, Inc (CNR) - Sherman Oaks
Connecticut
- Research Center for Clinical Studies, LLC - Norwalk
District of Columbia
- Re:Cognition Health - Fairfax - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2024-02-29 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06335173
The ClinicalTrials.gov registry entry for NCT06335173 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 542 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (80% lower). The listed sponsor is Acumen Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06335173 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06335173 about?
NCT06335173 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)". The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
What is the current status of trial NCT06335173?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 542 participants. The study started on 2024-02-29. Estimated completion is 2026-10.
What conditions does trial NCT06335173 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06335173?
The interventions under investigation include: Placebo (DRUG), sabirnetug (DRUG).
Who is sponsoring clinical trial NCT06335173?
This trial is sponsored by Acumen Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06335173 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.